Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TCRαβ/CD19 Depleted HSCT for Hematological Disorders
NCT04249830Phase 2Recruiting
- Start
- Feb 2020
- Primary completion
- Dec 2028
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of T-cell receptor alpha/beta and CD19 depleted hematopoietic stem cells in acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), juvenile myelomonocytic leukemia (JMML), mixed phenotype acute leukemia (MPAL). Started Feb 2020; status: recruiting.
02
Drugs
T-cell receptor alpha/beta and CD19 depleted hematopoietic stem cells
03
Conditions
acute lymphoblastic leukemia (ALL)acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)juvenile myelomonocytic leukemia (JMML)mixed phenotype acute leukemia (MPAL)
Beyond the preview
Go deeper on NCT04249830.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04249830.